Rani Therapeutics Holdings Stock Market Value
| RANI Stock | USD 1.24 0.01 0.80% |
| Symbol | Rani |
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value - what Rani Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Rani Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rani Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rani Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Rani Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Rani Therapeutics Holdings or generate 0.0% return on investment in Rani Therapeutics over 90 days. Rani Therapeutics is related to or competes with Innate Pharma, Milestone Pharmaceuticals, Cardiff Oncology, Corbus Pharmaceuticals, Sangamo Therapeutics, Elicio Therapeutics, and Molecular Partners. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered ... More
Rani Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rani Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rani Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 26.23 | |||
| Value At Risk | (7.50) | |||
| Potential Upside | 7.04 |
Rani Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rani Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rani Therapeutics' standard deviation. In reality, there are many statistical measures that can use Rani Therapeutics historical prices to predict the future Rani Therapeutics' volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 11.61 |
Rani Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 11.62 | |||
| Mean Deviation | 3.1 | |||
| Coefficient Of Variation | (756.60) | |||
| Standard Deviation | 4.65 | |||
| Variance | 21.64 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 11.61 | |||
| Maximum Drawdown | 26.23 | |||
| Value At Risk | (7.50) | |||
| Potential Upside | 7.04 | |||
| Skewness | 0.9859 | |||
| Kurtosis | 3.4 |
Rani Therapeutics Backtested Returns
Rani Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13 % return per unit of risk over the last 3 months. Rani Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Rani Therapeutics' Variance of 21.64, risk adjusted performance of (0.1), and Coefficient Of Variation of (756.60) to confirm the risk estimate we provide. The company holds a Beta of -0.0538, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Rani Therapeutics are expected to decrease at a much lower rate. During the bear market, Rani Therapeutics is likely to outperform the market. At this point, Rani Therapeutics has a negative expected return of -0.61%. Please make sure to check Rani Therapeutics' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Rani Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.49 |
Average predictability
Rani Therapeutics Holdings has average predictability. Overlapping area represents the amount of predictability between Rani Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rani Therapeutics price movement. The serial correlation of 0.49 indicates that about 49.0% of current Rani Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Rani Therapeutics Correlation, Rani Therapeutics Volatility and Rani Therapeutics Performance module to complement your research on Rani Therapeutics. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Rani Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.